Overview

Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Status:
Recruiting

Trial end date:
2023-02-28

Target enrollment:

Participant gender:

Summary

The purpose of study is to determine tolerability and safety profile of H3B-6545 in Japanese women with ER-positive, HER2-negative breast cancer, and also to confirm the dose applicability to Japanese.

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Co., Ltd.

Treatments:

Histamine Antagonists
Histamine H1 Antagonists